SAHA@LIPO-ANG2 therapeutic efficacy in 5xFAD mice

Validation Score: 0.900 Price: $0.50 Alzheimer's disease 5xFAD transgenic mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting HDAC4, NHE6 in 5xFAD transgenic mice. Primary outcome: Cognitive deficit reversal and Aβ burden reduction

Description

This comprehensive in vivo experiment evaluated the therapeutic efficacy of angiopep2-conjugated nanoparticles containing vorinostat (SAHA@LIPO-ANG2) in 5xFAD transgenic mice, an established Alzheimer's disease model. The study assessed multiple outcome measures including amyloid-β burden reduction, neuroinflammation suppression, synaptic loss rescue, and cognitive function improvement. The nanoparticle formulation was designed to overcome blood-brain barrier penetration limitations of conventional HDAC inhibitors. This experiment provided crucial preclinical validation of the nanotherapeutic approach and demonstrated the translation of the mechanistic findings into functional therapeutic benefits in a relevant animal model of Alzheimer's disease.

TARGET GENE

HDAC4, NHE6

MODEL SYSTEM

5xFAD transgenic mice

ESTIMATED COST

TIMELINE

0 months

PATHWAY

HDAC4-NHE6-pH regulatory axis, amyloid clearance pathways

SOURCE

extracted_from_pmid_41933339

PRIMARY OUTCOME

Cognitive deficit reversal and Aβ burden reduction

Scoring Dimensions

📖 Wiki Pages

HDAC4 Proteinprotein HDAC4 Proteinprotein HDAC4 Genegene HDAC Inhibitors for Neurodegeneration — Investmentinvestment HDAC Inhibitorstherapeutics HDAC Inhibitor Mechanism in Neurodegenerationmechanism HDAC Inhibitors for Neurodegenerative Diseasestherapeutic APP Mutations in Alzheimer's Diseasedisease Alzheimer's Disease vs Parkinson's Disease Comparidisease Alzheimer's Diseasedisease Prodromal Alzheimer's Diseasedisease PSEN1 Mutations in Alzheimer's Diseasedisease PSEN2 Mutations in Alzheimer's Diseasedisease Sporadic vs Familial Alzheimer's Disease: Comprehedisease Preclinical Alzheimer's Diseasedisease

Protocol

Establish 5xFAD transgenic mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for HDAC4, NHE6, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure Cognitive deficit reversal and Aβ burden reduction together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting HDAC4, NHE6 shifts Cognitive deficit reversal and Aβ burden reduction in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Significant reduction in Aβ plaques, decreased neuroinflammatory markers, restored synaptic proteins, improved performance in cognitive tests

Related Hypotheses (5)

ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia0.869

TREM2-mediated microglial tau clearance enhancement0.618

LRP1-Dependent Tau Uptake Disruption0.600

VCP-Mediated Autophagy Enhancement0.595

Extracellular Vesicle Biogenesis Modulation0.582

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.